Surgery Partners (SGRY) EBITDA (2014 - 2026)

Surgery Partners (SGRY) has 13 years of EBITDA data on file, last reported at $65.8 million in Q1 2026.

• Quarterly EBITDA rose 6.3% year-over-year to $65.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $393.4 million (up 17.54% YoY) and the FY2025 annual result came in at $559.7 million, up 13.39% from the prior year.
• EBITDA fell to $65.8 million in Q1 2026 per SGRY's latest filing, from $110.2 million in the prior quarter.
• The five-year high for EBITDA was $127.1 million in Q4 2024, with the low at $46.4 million in Q1 2023.
• Average EBITDA over 5 years is $86.9 million, with a median of $84.8 million recorded in 2024.
• Year-over-year, EBITDA sank 53.78% in 2023 and soared 73.56% in 2025.
• Surgery Partners' EBITDA stood at $94.2 million in 2022, then climbed by 7.64% to $101.4 million in 2023, then increased by 25.35% to $127.1 million in 2024, then dropped by 13.3% to $110.2 million in 2025, then tumbled by 40.29% to $65.8 million in 2026.
• Business Quant data shows SGRY's EBITDA at $65.8 million in Q1 2026, $110.2 million in Q4 2025, and $105.7 million in Q3 2025.